Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB054 in Japanese participants with early Parkinson's disease
jRCT2080224171Phase 1Completed
- Sponsor
- Biogen
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of cinpanemab in Parkinson's disease (PD), sponsored by Biogen. Primary endpoint: Safety and tolerability of BIIB054. Started Dec 2018; status: completed.
02
Drugs
cinpanemab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080224171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224171.